Shrewsbury Latest News (Massachusetts, United States)

First of its kind Summit by ISW brings together leaders, innovators, and professionals for a transformative day of growth and connection in Shrewsbury, MA

SignaBlok will present groundbreaking positive preclinical data detailing therapeutic activity of its leading macrophage-restricted TREM-1 inhibitor in experimental sepsis, acute respiratory distress syndrome (ARDS), and pulmonary fibrosis (PF)

SignaBlok, Inc. will present groundbreaking preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence